Tumoral cubilin is a predictive marker for treatment of renal cancer patients with sunitinib and sorafenib.

ABSTRACT:

Purpose

Tyrosine kinase inhibitors like sunitinib and sorafenib are commonly used to treat metastatic renal cell cancer patients. Cubilin is a membrane protein expressed in the proximal renal tubule. Cubilin and megalin function together as endocytic receptors mediating uptake of many proteins. There is no established predictive marker for metastatic renal cell cancer patients and the purpose of the present study was to assess if cubilin can predict response to treatment with tyrosine kinase inhibitors.

Methods

Cubilin protein expression was analyzsed in tumor tissue from a cohort of patients with metastatic renal cell cancer (n = 139) using immunohistochemistry. One hundred and thirty six of the patients were treated with sunitinib or sorafenib in the first- or second-line

SUBMITTER: Niinivirta M 

PROVIDER: S-EPMC5427164 | biostudies-literature | 2017 Jun

REPOSITORIES: biostudies-literature